Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Xeris Pharmaceuticals Inc
(NQ:
XERS
)
1.760
-0.120 (-6.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xeris Pharmaceuticals Inc
< Previous
1
2
3
Next >
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
March 08, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
February 23, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
February 02, 2023
From
Xeris Biopharma, Inc.
Via
Business Wire
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
January 30, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Updates Its Outlook For 2022
January 05, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
December 15, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
November 23, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events
November 09, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022
November 02, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology
November 01, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
October 20, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
August 10, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
August 03, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
August 01, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
May 12, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
May 11, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
May 04, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
March 16, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Xeris Biopharma Holdings
Via
Business Wire
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
January 31, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update
January 18, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
January 06, 2022
From
Xeris Biopharma
Via
Business Wire
Xeris Biopharma Enters Into Agreement for $30 Million Private Placement
January 03, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
December 30, 2021
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma
December 16, 2021
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights
November 10, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021
November 02, 2021
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Enters Collaboration Agreement With Merck
October 25, 2021
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
October 05, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.